Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Given the lack of other viable treatment options for metastatic neuroendocrine tumors,
contrasted with our positive anecdotal experience, and the relative tolerability of the
treatment regimen for colorectal cancer patients, we propose a single-institution phase II
trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients
with metastatic neuroendocrine tumors.